Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.040
-0.050 (-4.59%)
At close: Nov 6, 2026, 4:00 PM EST
1.060
+0.020 (1.92%)
After-hours: Nov 6, 2026, 7:57 PM EST

Allogene Therapeutics Revenue

Allogene Therapeutics had revenue of $4.64M in the twelve months ending September 30, 2026. That makes Allogene Therapeutics the 40,253rd largest company in the world by revenue and 5,344th in the United States.

Revenue (ttm)
$4.64M
Revenue Growth
n/a
P/S Ratio
77.66
Revenue / Employee
$30,526
Employees
152
Market Cap
360.33M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025---
Dec 31, 202422.00K-73.00K-76.84%
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Alector173.47M
Fennec Pharmaceuticals59.22M
Prelude Therapeutics22.42M
Opus Genetics9.86M
ProKidney818.00K
Lyell Immunopharma15.00K
Revenue Rankings